KR102496029B1 - Novel Ganoderma lucidum GUC211 and antidiabetic composition comprising it - Google Patents

Abstract

The present invention relates to a novel Ganoderma lucidum GUC211 ( Ganoderma lucidum GUC211, accession number: KCTC14321BP) having a hypoglycemic effect. It can be usefully used for the early prevention, improvement, and treatment of diabetes, which is the cause of diabetes.

Description

Novel Ganoderma lucidum GUC211 and antidiabetic composition comprising it}

The present invention relates to a novel Ganoderma lucidum GUC211 ( Ganoderma lucidum GUC211, accession number: KCTC14321BP) having hypoglycemic effect and an antidiabetic composition containing the same.

Despite the great development of modern life science in relation to changes in eating habits, aging of the population, and various stresses due to recent economic development, the incidence of cardiovascular diseases and metabolic diseases, including cancer, is also on the rise. In particular, among the metabolic diseases, diabetes is a chronic wasting disease characterized by abnormal glucose metabolism due to absolute deficiency or resistance of insulin, and causes various other complications such as systemic lethargy and resistance decrease, vascular disorder, cerebral infarction, and myocardial infarction. am. Also, according to the World Health Organization (WHO), 350 million people suffer from diabetes, and by 2030, that number is expected to double.

Diabetes is largely divided into two types depending on the cause and condition. Diabetes is an insulin-dependent diabetes mellitus that occurs when insulin secretion does not proceed normally due to the destruction of beta cells of the islets of Langerhans due to specific human lymphocyte antigen (HLA) and viral infection. There is type 1 diabetes, and type 2 diabetes, which is non-insulin dependent, caused by increased resistance to insulin in peripheral tissues such as muscle, liver, and adipose tissue due to lack of exercise, obesity, overeating, and stress. In particular, due to the aging of modern society and changes in lifestyle, type 2 diabetes accounts for more than 90% of all diabetes patients, and the number is steadily increasing. The main cause of type 2 diabetes is insulin resistance, which refers to a state in which the response to a certain amount of insulin concentration is reduced than normal, and is generally caused by genetic and environmental factors.

Reishi mushroom ( Ganoderma lucidum ) develops on the roots of broad-leaved trees in summer. It is also known as Qin Shi Huang's herb of immortality, and in Herbal Medicine, along with ginseng, this mushroom was placed in the ranks of medicinal herbs. Reishi mushroom has effects such as tonic, antitussive, and sore throat, so it is effective for respiratory diseases, nervous breakdown, heart disease, and high blood pressure, and is also known to lower cholesterol and have anticancer effects.

On the other hand, in order to use mushrooms as a mixed raw material for pharmaceuticals and functional foods, mushrooms, which are fruiting bodies, must be collected and used, but the problem that mushrooms themselves do not reproduce well in nature, and resource depletion and ecosystem destruction are caused by abuse of collection there is A method of cultivating fruit bodies using sawdust, etc. is also used, but this method also takes several months only for the cultivation period. Even in order to supply raw materials to the extent that they can be used industrially, it is difficult to meet the demand for mass production due to the difficulty of requiring a large amount of production facilities and expenses. As such, even though the mushrooms are effective as anticancer agents or immune enhancers, their supply is limited and mass production and rapid production are not easy, so they are not widely used. Therefore, for the above mushrooms, research on mass cultivation methods capable of producing mycelium that can produce mycelium that exhibits the same effect as the fruiting body of mushroom fungi has been actively conducted recently, and studies to explore new mushroom species that can be mass-produced are also in progress in progress

Accordingly, the inventors of the present invention completed the present invention by discovering a novel Ganoderma lucidum mushroom and confirming its excellent blood sugar lowering effect while studying the physiological activity of various mushrooms, including Ganoderma lucidum.

Republic of Korea Patent Registration No. 10-1072834 (Title of invention: Polysaccharide fraction for lowering blood sugar prepared by fermenting ginseng with ganoderma lucidum mycelium, Applicant: Korea Food Research Institute, registration date: October 6, 2011) Republic of Korea Patent Publication No. 10-2005-0019499 (Title of Invention: Extracellular polysaccharide or intracellular polysaccharide having anti-diabetic effect produced from liquid culture of mycelium of Ganoderma lucidum, Applicant: TG Biotech Co., Ltd. and 2 others, Publication date: 2005 03/03/2017)

An object of the present invention is to provide a new Ganoderma lucidum GUC211 ( Ganoderma lucidum GUC211, accession number: KCTC14321BP) having hypoglycemic effect and an antidiabetic composition containing the same.

The present invention relates to a novel Ganoderma lucidum GUC211 ( Ganoderma lucidum GUC211, accession number: KCTC14321BP).

The ganoderma lucidum GUC211 has a hypoglycemic effect, and preferably has a hypoglycemic effect in both type 1 diabetes and type 2 diabetes.

The ganoderma lucidum GUC211 can be cultured in PDA (Potato Dextrose Agar), PDB (Potato Dextrose Broth), MCM (mushroom complete medium), etc., and is mainly parasitic on woody trees and broad-leaved trees such as oak, plum tree, and chestnut.

In addition, the ganoderma lucidum GUC211 can be cultured in a mycelial or fruiting body state, and can be mass-cultivated in a mycelial state with higher antidiabetic activity using the following method.

(Step 1) inoculating fruiting body tissues of Ganoderma lucidum GUC211 on PDA (Potato Dextrose Agar) and culturing them as mycelium;

(Second step) inoculating the mycelium of Ganoderma lucidum GUC211 cultured in the first step into PDB (Potato Dextrose Broth);

(Step 3) Cultivating PDB (Potato Dextrose Broth) inoculated with mycelium of Ganoderma lucidum GUC211 for 4 to 6 weeks;

(Fourth step) inoculating the GUC211 mycelium of Ganoderma lucidum obtained through the third step of culturing in a barley medium;

(Step 5) obtaining a mass-produced GUC211 mycelium of Ganoderma lucidum by additionally culturing GUC211 mycelium of Ganoderma lucidum inoculated in rice barley medium for 4 to 7 weeks;

It can be cultured, including.

The mycelium culture of the third step is preferably performed at a relative humidity of 10 to 30% and 25 to 30 ° C. In addition, the initial 1 to 2 weeks of static culture, but it is preferable to stir for 1 to 5 minutes for 1 to 2 times per day cycle, and after that, shaking culture with stirring at 50 to 150 rpm is good for culturing the mycelium.

The barley medium in the fourth step is dehydrated after soaking the barley for 4 to 8 hours, adding 0.5 to 2 parts by weight of calcium carbonate based on 100 parts by weight of the dehydrated barley, and then sterilizing at 120 to 125 ° C for 30 minutes to 2 hours. may have been obtained by

The culturing in the fifth step is preferably carried out at a relative humidity of 40 to 60% and at 25 to 30°C.

PDA (Potato Dextrose Agar) used for culturing mushroom mycelium in the present invention is prepared by sterilizing 3 to 5 g of potato starch, 10 to 30 g of dextrose, and 10 to 30 g of agarose based on a total volume of 1 liter. can At this time, water may be added so that the total volume is 1 liter as a residual amount. The sterilization is preferably carried out at least 120 ~ 125 ℃ for 15 ~ 20 minutes. The most preferable condition for producing PDA (Potato Dextrose Agar) may be sterilization by adding water to 4 g of potato starch, 20 g of dextrose, and 15 g of agarose to a total volume of 1 L.

In addition, PDB (Potato Dextrose Broth) used for culturing mushroom mycelium in the present invention may be prepared by adding more water instead of agarose in the manufacturing conditions of PDA (Potato Dextrose Agar). PDB (Potato Dextrose Broth) is most preferably prepared by sterilizing 4 g of potato starch and 20 g of dextrose by adding water to a total volume of 1 L.

When culturing the mushroom fruiting body as a mycelium in the first step, it is preferable to inoculate the mushroom fruiting body pieces into PDA (Potato Dextrose Agar) and then incubate them at 25 to 30 ° C for 1 to 3 weeks. It can be properly controlled within 1 to 3 weeks depending on the growth potential of the mushroom fruiting body. In addition, it is more preferable that the relative humidity at the time of cultivation under this condition is 10 to 60%. Mycelial growth can be slow even when humidity is below 10% or above 60%.

However, if the incubation period is less than 1 week, the mycelia may not grow well enough to activate the subsequent liquid culture, and even if the culture period exceeds 3 weeks, the mycelia may not be cultured well during subsequent liquid culture. In addition, even if the culture temperature is less than 25 ℃ or exceeds 30 ℃, it is also undesirable to affect the mycelium culture during liquid culture.

When inoculating the mycelium into PDB (Potato Dextrose Broth) in the second step, the mycelium may be inoculated to a similar level in a certain amount, but more preferably, the cultured mycelium is cut into 0.5 to 2 mm square and 3 to 20 pieces each. Three types of mycelium can be inoculated in PDB (Potato Dextrose Broth).

The mycelium culture in the third step is preferably performed at 25 to 30 ° C. In particular, when the culture temperature is less than 25 ° C, the mycelium may not grow well, and even if the temperature exceeds 30 ° C, the culture of the mycelium may also be slow. . In addition, the initial 1 to 2 weeks of static culture, but it is preferable to stir for 1 to 5 minutes for 1 to 2 times per day cycle, and after that, shaking culture with stirring at 50 to 150 rpm is good for culturing the mycelium. On the other hand, the relative humidity at the time of culturing under these conditions is not greatly limited, but preferably a relative humidity of 10 to 30%.

Based on 1 kg of rice barley medium in the fourth step, the mycelium obtained through the culture in the third step may be inoculated in 1 to 10 ml in a culture medium. At this time, if the mycelium culture medium is inoculated in less than 1 ml, additional culture in rice barley medium may not work well, and even if the culture medium is inoculated in excess of 10 ml, the culture is not further activated, which is not preferable.

The barley medium in the fourth step is dehydrated after soaking the barley for 4 to 8 hours, adding 0.5 to 2 parts by weight of calcium carbonate based on 100 parts by weight of the dehydrated barley, and then sterilizing at 120 to 125 ° C for 30 minutes to 2 hours. may have been obtained by At this time, if barley is not sufficiently soaked in water and soaked for less than 4 hours, it may not be able to use rice barley as a nutrient source due to lack of moisture during mycelium cultivation. Since it is not absorbed by rice barley, it is undesirable because it only delays the manufacturing time.

The culturing of the fifth step is preferably performed at 25 to 30 ° C. If the incubation temperature is less than 25 ℃, the mycelium may not grow well, and even if it exceeds 30 ℃, the culture of the mycelium may also be slow. In addition, it is more preferable that the relative humidity at the time of culturing under these conditions is 40 to 60%. Mycelium growth can be slow even when the humidity is below 40% or above 60%.

In addition, the present invention can provide the mycelium, fruit body, or extracts of the novel Ganoderma lucidum GUC211 in various types of processed products.

The extract of Ganoderma lucidum GUC211 can be extracted from Ganoderma lucidum GUC211 using water, C1-C4 alcohol, or a mixture thereof as a solvent, and the C1-C4 alcohol is methanol, ethanol, propanol, isopropanol, butanol and isobutanol. can be selected from the group consisting of

Water, C1-C4 alcohol, or a mixture thereof used in the preparation of the ganoderma lucidum GUC211 extract may be 1 to 40 times the volume (1 to 40 ℓ based on 1 kg) based on the weight of ganoderma lucidum GUC211 used, preferably 5 to 40 liters per kg. 40 times the volume can be used. The extraction condition of the ganoderma lucidum GUC211 may be 1 minute to 48 hours at 20 to 100 ° C. The above process may be repeated from 1 to 4 times.

In addition, as a conventional method in the art, after dissolving water, C1-C4 alcohol, or a mixture solution extract of the Ganoderma lucidum GUC211 in water, n-hexane, methylene chloride, acetone, chloroform, ethyl acetate and n-butanol are prepared. It may be prepared into fractions by additionally fractionating using one or more solvents selected from the group.

In another method, Ganoderma lucidum GUC211 obtained by extracting and concentrating Ganoderma lucidum GUC211 with water, C1-C4 alcohol or a mixed solvent thereof is suspended by adding water to the Ganoderma lucidum GUC211 extract, preferably 1 of the weight of ~ 1000 times, more preferably 1 ~ 500 times, most preferably 1 ~ 50 times water is added and suspended, and a solvent selected from the group consisting of hexane, chloroform, ethyl acetate, and butanol is added to the suspension It can be prepared from the erythropleum pordi fraction obtained by adding The ganoderma lucidum GUC211 fraction is preferably, a concentrate of the hexane layer obtained by suspending the ganoderma ganoderma GUC211 extract obtained by extracting and concentrating ganoderma ganoderma GUC211 with water, C1-C4 alcohol, or a mixed solvent thereof in water and then mixing it with hexane. , The concentrate of the chloroform layer obtained by mixing chloroform with the residue (aqueous layer) remaining after removing the hexane layer, or the concentrate of the ethyl acetate layer obtained by mixing ethyl acetate with the residue (aqueous layer) remaining after removing the chloroform layer, It may be a concentrate of the butanol layer obtained by mixing butanol with the residue (aqueous layer) remaining after removing the ethyl acetate layer, or a concentrate of the residue (aqueous layer) remaining after removing the butanol layer. On the other hand, other fractionation conditions are not limited, but 1 to 50 times the weight of the ganoderma lucidum GUC211 extract is added to water to prepare a suspension, and then hexane, chloroform, ethyl in the same amount as the water It may be fractionated by adding a solvent selected from the group consisting of acetate and butanol. In addition, when chloroform is added to the residue remaining after removing the hexane layer, ethyl acetate is added to the residue remaining after removing the chloroform layer, and butanol is added to the residue remaining after removing the ethyl acetate, the same amount of It can be fractionated by sequentially adding each solvent (chloroform, ethyl acetate or butanol).

The preparation temperature of the extract or its fraction may be 20 to 100 ℃, but is not limited thereto. The extraction or fractionation time is not particularly limited, but it is preferable to extract within 10 minutes to 2 days, and as a device for extraction, a conventional extraction device, an ultrasonic crusher or a fractionator may be used. The solvent can be removed from the ganoderma lucidum GUC211 extract or fraction prepared in this way by hot air drying, vacuum drying or lyophilization. In addition, the ganoderma lucidum GUC211 extract or fraction may be used after being purified using column chromatography.

The ganoderma lucidum GUC211 extract is obtained by a known method used for separation and extraction of plant components, such as extraction with an organic solvent (alcohol, ether, acetone, etc.), distribution of hexane and water, and column chromatography, according to a conventional method. Alternatively, it may be used after fractionation or purification using a suitably combined method.

The chromatography is silica gel column chromatography, LH-20 column chromatography, ion exchange resin chromatography, medium pressure liquid chromatography chromatography), thin layer chromatography (TLC), silica gel vacuum liquid chromatography, and high performance liquid chromatography.

In the present invention, ganoderma lucidum GUC211 refers to its fruiting body, mycelium, extract or various processed products.

On the other hand, the present invention provides a pharmaceutical composition for anti-diabetes containing ganoderma lucidum GUC211. The ganoderma lucidum GUC211 may be added in an amount of 0.001 to 100% by weight in the pharmaceutical composition of the present invention.

The pharmaceutical composition may be formulated and used in the form of oral formulations such as powders, granules, tablets, capsules, suspensions, emulsions, syrups, aerosols, external preparations, suppositories and sterile injection solutions according to conventional methods, respectively. Carriers, excipients, and diluents that may be included in the pharmaceutical composition include lactose, dextrose, sucrose, sorbitol, mannitol, xylitol, erythritol, maltitol, starch, gum acacia, alginate, gelatin, calcium phosphate, calcium silicate, and cellulose. , methyl cellulose, microcrystalline cellulose, polyvinyl pyrrolidone, water, methylhydroxybenzoate, propylhydroxybenzoate, talc, magnesium stearate and mineral oil. When formulated, it is prepared using diluents or excipients such as commonly used fillers, extenders, binders, wetting agents, disintegrants, and surfactants. Solid preparations for oral administration include tablets, pills, powders, granules, capsules, etc. These solid preparations include at least one excipient, for example, starch, carbonic acid, in the pharmaceutical composition containing Ganoderma lucidum GUC211 of the present invention It is prepared by mixing calcium, sucrose or lactose, and gelatin. In addition to simple excipients, lubricants such as magnesium stearate and talc are also used. Liquid preparations for oral use include suspensions, solutions for oral use, emulsions, syrups, etc. In addition to water and liquid paraffin, which are commonly used simple diluents, various excipients such as wetting agents, sweeteners, aromatics, and preservatives may be included. . Formulations for parenteral administration include sterilized aqueous solutions, non-aqueous solvents, suspensions, emulsions, freeze-dried formulations, and suppositories. Propylene glycol, polyethylene glycol, vegetable oils such as olive oil, and injectable esters such as ethyl oleate may be used as non-aqueous solvents and suspensions. As a base for the suppository, witepsol, macrogol, tween 61, cacao butter, laurin paper, glycerogeratin and the like may be used.

The dosage of the pharmaceutical composition of the present invention will vary depending on the age, sex, and weight of the subject to be treated, the specific disease or pathological condition to be treated, the severity of the disease or pathological condition, the route of administration, and the judgment of the prescriber. Determination of dosage based on these factors is within the level of those skilled in the art, and generally dosages range from 0.01 mg/kg/day to approximately 2000 mg/kg/day. A more preferred dosage is 1 mg/kg/day to 500 mg/kg/day. Administration may be administered once a day, or may be administered in several divided doses. The dosage is not intended to limit the scope of the present invention in any way.

The pharmaceutical composition of the present invention can be administered to mammals such as rats, livestock, and humans through various routes. All modes of administration are contemplated, eg oral, rectal or intravenous, intramuscular, subcutaneous, intrauterine intrathecal or intracerebrovascular injection. Since the extract of the present invention has little toxicity and side effects, it is a drug that can be safely used even when taken for a long period of time for preventive purposes.

In addition, the present invention provides a health functional food for anti-diabetes including ganoderma lucidum GUC211 or various processed products thereof together with food additives acceptable in food science. The ganoderma lucidum GUC211 may be added to the health functional food of the present invention in an amount of 0.001 to 100% by weight. The health functional food of the present invention includes forms such as tablets, capsules, pills or liquids, and foods to which the Ganoderma lucidum GUC211 of the present invention can be added include, for example, various drinks, meat, sausages, bread, Candies, snacks, noodles, ice cream, dairy products, soups, ionic beverages, soft drinks, alcoholic beverages, gum, tea, and vitamin complexes.

The present invention relates to a novel Ganoderma lucidum GUC211 ( Ganoderma lucidum GUC211, accession number: KCTC14321BP) having a hypoglycemic effect. It can be usefully used for the early prevention, improvement, and treatment of diabetes, which is the cause of diabetes.

1 shows the gene sequence of the inter transscribed spacer (ITS) region of the 18s rRNA of the novel Ganoderma lucidum GUC211 of the present invention.
Figure 2 shows the shape of the fruiting body and mycelium of the novel ganoderma lucidum GUC211 of the present invention.

Hereinafter, preferred embodiments of the present invention will be described in detail. However, the present invention is not limited to the embodiments described herein and may be embodied in other forms. Rather, it is provided to sufficiently convey the spirit of the invention to those skilled in the art, so that the disclosure herein will be thorough and complete.

<Example 1. Genetic identification of novel ganoderma lucidum GUC211>

After collecting wild Ganoderma lucidum in various ways and screening them for antidiabetic activity, the Ganoderma lucidum with the highest antidiabetic activity was first called GUC211, and genetic identification was performed on this.

Cosmogenetech Co., Ltd. was commissioned to determine the nucleotide sequence of GUC211, and the primers used to isolate the ITS (Inter transscribed spacer) region of 5.8s rRNA from the genomic DNA of GUC211 were already in the gene region of fungal ITS 5.8s rRNA. ITS 1 (5'-TCCGTAGGTGAACCTGCGG-3', SEQ ID NO: 1) and ITS 4 (5'-TCCTCCGCTTATTGATATGC-3', SEQ ID NO: 2) developed to be amplified by PCR were used. As a result, the ITS base sequence (SEQ ID NO: 3) as shown in Figure 1 was confirmed (Figure 1), showing more than 99% homology with the existing Ganoderma lucidum , but not 100% matching with other Ganoderma lucidum, so it is a new After confirming that it was a Ganoderma lucidum, the GUC211 mushroom was named Ganoderma lucidum GUC211 and deposited with the Korea Center for Biological Resources under the accession number KCTC14321BP.

<Example 2. Culture of ganoderma lucidum GUC211 mycelium>

In order to confirm the efficacy of Ganoderma lucidum GUC211, mycelia of new Ganoderma lucidum GUC211 were obtained using the mycelium culture method developed by Giunchan Co., Ltd.

After separating the fruiting body tissue of Ganoderma lucidum GUC211 and inoculating it on PDA, it was incubated as a mycelium at 27~29℃ for 2 weeks. After preparing the PDB medium subdivided into 100 ml units, the mushroom mycelium cultured in the PDA was cut into 1 mm square using a scalpel, and 15 pieces of the cut strain were inoculated per Erlenmeyer flask containing the PDB medium.

The medium inoculated with the mycelium fragments was incubated in a BOD incubator (Bio-Oxygen Demand incubator, low-temperature incubator) for 1 week at 27-28 ° C and 20% humidity, and stirred for 1 minute every day during the culture. After one week, the inoculated and cultured flask was moved to a shaker and cultured at 27 ° C. and 100 rpm for 4 weeks to prepare a mycelium culture medium.

Barley was soaked in water for 6 hours, then dehydrated for 8 hours, 1 g of calcium carbonate was added based on 100 g of dehydrated barley, mixed evenly, and sterilized in a high-pressure sterilizer at 121 ° C. for 1 hour to prepare a barley medium. After the end of sterilization, 5 ml of mycelial culture medium cultured for 5 weeks per 1 kg of rice barley medium cooled to 25 ° C. was divided and inoculated. After inoculation, it was cultured for 30 days in a culture room maintained at a temperature of 26 to 28 ° C and a humidity of 45 to 50%.

The cultured mycelium was dried for 24 hours at 57 ~ 60 ° C. using a dryer while containing rice barley, and pulverized using a pin mill grinder to prepare powder.

In this way, the mycelium of Ganoderma lucidum GUC211 was cultured in large quantities.

On the other hand, this method is an application of the complex culture method of three types of mushrooms disclosed in Example 1 of Korean Patent Registration No. 10-1923408.

<Experimental Example 1. Confirmation of blood glucose control effect in type 1 diabetic animal model>

An animal model for type 1 diabetes was induced by intravenous injection of Alloxan (Alloxan, Sigma, MA, USA) at an amount of 50 mg/kg to ICR mice (male, 7 weeks old, 7 mice per group). In the experimental group, dried mushroom mycelium powder was suspended in PBS (Phosphate buffered saline) and orally administered at 5 mg/mouse once a day from 3 days before alloxan administration. In addition, blood was collected on the 9th day after administration of alloxan, and the blood glucose content was measured and shown in Table 1 below.

condition blood glucose (mg/dL) alloxan
martial arts lady positive control
(Alloxan alone administration group) Alloxan +
GUC211 mycelium
5mg/mouse administration group Alloxan +
Commercial Reishi Mushroom
5mg/mouse
administration group 9 days 98 582 135 324

Referring to Table 1, it can be confirmed that blood glucose levels in animals in the GUC211 mycelium-administered group of the present invention were maintained closer to those in the Alloxan non-administered group throughout the administration period.

<Experimental Example 2. Confirmation of blood glucose control effect in type 2 diabetic animal models>

As an animal model for type 2 diabetes, db/db diabetic mice (5 weeks old, male) were purchased and used. In the experimental group, dry powder of GUC211 ganoderma lucidum mycelium was suspended in PBS and orally administered at 5 mg/mouse once a day for 8 weeks, and then the blood glucose content was measured and shown in Table 2 below.

condition blood glucose (mg/dL) martial arts lady GUC211 mycelium
5mg/mouse administration group Commercial Reishi Mushroom
5mg/mouse
administration group 8 weeks 412 172 301

db / db diabetic mice are characterized in that the blood glucose concentration is maintained at 390 ~ 420 mg / dL, but from the results of Table 2, it can be confirmed that blood sugar is significantly reduced in the mycelium-administered group of Ganoderma lucidum GUC211 compared to the untreated group. .

<Experimental Example 3. Confirmation of blood sugar lowering effect through direct administration>

Five people in their 40s to 60s who have experienced symptoms measured as hyperglycemic conditions (pre-diabetes status, diabetes must exceed 130mg/dl) with a fasting blood sugar of 110-130mg/dl measured for 10 days or more in 1 month The mycelium of Reishi mushroom GUC211 was taken for one month, and the period during which fasting blood sugar increased to 110 mg/dl or more was measured during the intake period. They were not provided with a designated meal plan, but were instructed to take 5 g of each granule within 30 minutes after each meal. The measured values are shown in Table 9 below, and the number of hyperglycemic symptoms per group was described as the average value. Decimal points of the average value were rounded down. At this time, the group that consumed general Ganoderma lucidum powder sold on the market was set as a comparison group.

condition Number of times of high blood sugar in 1 month while taking GUC211 mycelium 2 Commercial Reishi Mushroom 6

As a result of the confirmation, as shown in Table 3, it can be seen that the number of hyperglycemias for 1 month was significantly reduced in the group taking the mycelium of Ganoderma lucidum GUC211, and the effect was better than that of general Ganoderma lucidum for sale.

<Formulation Example 1. Pharmaceutical formulation>

Formulation Example 1-1. manufacture of tablets

200 g of dry mycelium powder of Ganoderma lucidum GUC211 of the present invention was mixed with 175.9 g of lactose, 180 g of potato starch and 32 g of colloidal silicic acid. After adding 10% gelatin solution to this mixture, it was pulverized and passed through a 14 mesh sieve. It was dried and the mixture obtained by adding 160 g of potato starch, 50 g of talc and 5 g of magnesium stearate was made into tablets.

<Formulation Example 2. Food Manufacturing>

Formulation Example 2-1. Preparation of seasoning for cooking

Ganoderma lucidum GUC211 fruiting body dried powder of the present invention was added to the cooking seasoning at 1% by weight to prepare a cooking seasoning for health promotion.

Formulation example 2-2. Manufacture of Flour Food

Ganoderma lucidum GUC211 fruiting body dry powder of the present invention was added to wheat flour at 0.1% by weight, and bread, cakes, cookies, crackers, and noodles were prepared using the mixture to prepare health-promoting foods.

Formulation Example 2-3. Preparation of soups and gravies

The dry powder of Ganoderma lucidum GUC211 mycelium of the present invention was added to soup and broth in an amount of 0.1% by weight to prepare soup and broth for health promotion.

Formulation Example 2-4. Manufacture of dairy products

The lyophilized product of the hot-water extract of Ganoderma lucidum GUC211 mycelium of the present invention was added to milk in an amount of 0.1% by weight, and various dairy products such as butter and ice cream were prepared using the milk.

Formulation Example 2-5. vegetable juice manufacturing

Vegetable juice for health promotion was prepared by adding 0.5 g of the freeze-dried product of the Ganoderma lucidum GUC211 mycelium hot-water extract of the present invention to 1,000 ml of tomato juice or carrot juice.

Formulation Example 2-6. fruit juice manufacturing

0.1 g of the freeze-dried product of the hot-water extract of Ganoderma lucidum GUC211 mycelium of the present invention was added to 1,000 ml of apple juice or grape juice to prepare fruit juice for health promotion.

[Entrusted institution]

Name of Depositary Institution: Korea Center for Biological Resources

Accession number: KCTC14321BP

Entrusted date: 20200925

<110> Giunchan Co.,Ltd <120> Novel Ganoderma lucidum GUC211 and antidiabetic composition comprising it <160> 3 <170> KoPatentIn 3.0 <210> 1 <211> 19 <212> DNA <213> artificial sequence <220> <223> <400> 1 tccgtaggtg aacctgcgg 19 <210> 2 <211> 20 <212> DNA <213> artificial sequence <220> <223> <400> 2 tcctccgctt attgatatgc 20 <210> 3 <211> 568 <212> DNA <213> unknown <220> 223 <Ganoderma lucidum> <400> 3 ccgaggcatg tgcacgccct gctcatccac tctacacctg tgcacttact gtgggcttca 60 gattgcgagg cacgctcttt accgggcttg cggagcatat ctgtgcctgc gtttatcaca 120 aactctataa agtaacagaa tgtgtattgc gatgtaacac atctatatac aactttcagc 180 aacggatctc ttggctctcg catcgatgaa gaacgcagcg aaatgcgata agtaatgtga 240 attgcagaat tcagtgaatc atcgaatctt tgaacgcacc ttgcgcccct tggtattccg 300 aggagcatgc ctgtttgagt gtcatgaaat cttcaaccta caagcttttg tggtttgtag 360 gcttggactt ggaggcttgt cggccgttat cggtcggctc ctcttaaatg cattagcttg 420 gttccttgcg gatcggctct cggtgtgata atgtctacgc cgcgaccgtg aagcgtttgg 480 cgagcttcta accgttttat aagacagctt tatgacctct gacctcaaat caggtaggac 540 tacccgctga acttaagcat atcaataa 568

Claims (6)

A novel Ganoderma lucidum GUC211 ( Ganoderma lucidum GUC211, accession number: KCTC14321BP), characterized in that it has a hypoglycemic effect in type 1 and type 2 diabetes and contains the gene of SEQ ID NO: 3. delete delete An anti-diabetic health functional food containing Ganoderma lucidum GUC211 ( Ganoderma lucidum GUC211, accession number: KCTC14321BP) of claim 1, which has a blood sugar lowering effect in type 1 and type 2 diabetes. A pharmaceutical composition for preventing or treating type 1 diabetes and type 2 diabetes, characterized in that it contains the ganoderma lucidum GUC211 of claim 1 ( Ganoderma lucidum GUC211, accession number: KCTC14321BP). A health functional food for preventing or improving type 1 diabetes and type 2 diabetes, characterized in that it contains the ganoderma lucidum GUC211 of claim 1 ( Ganoderma lucidum GUC211, accession number: KCTC14321BP).

Images